Dabigatran etexilate
-
- 应用范围
- Inhibition Assay (InhA), Functional Studies (Func)
- 原理
- Dabigatran etexilate is an oral prodrug that is metabolized by a serum esterase to dabigatran. It is a synthetic, competitive and reversible direct thrombin inhibitor. Inhibition of thrombin disrupts the coagulation cascade and inhibits the formation of clots. Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients who have undergone total hip or knee replacement surgery, or to prevent stroke and systemic embolism in patients with atrial fibrillation, in whom anticoagulation therapy is indicated. In contrast to warfarin, because its anticoagulant effects are predictable, lab monitoring is not necessary. FDA approved on October 19, 2010.
- 产品特性
-
Tradename: PRADAXA
Source of Compound: synthetic, BIBR-1048
Target: Thrombin inhibitor
Receptor: Thrombin
- 纯化方法
- All the products are sent with COA, HPLC and NMR inspection report to guarantee the quality.
- 纯度
- 98 %
- Formula
- C34H41N7O5
- Solubility
- Soluble in water
-
-
- 应用备注
- Optimal working dilution should be determined by the investigator.
- 限制
- 仅限研究用
-
- 状态
- Solid
- 储存条件
- -20 °C
- 储存方法
-
For the majority of compounds, they could be dissolved in DMSO or other organic solvent.
Their stock solution can be stored at -20°C for up to 3 months and aliquoted for sampling convenience.
Several freeze/thaw cycles should not damage the activity of our small molecule products.
However, in many instances the aqueous solutions of some compounds need to be made fresh and cannot be stored. For these compounds, their solution should be prepared just before use and stored no longer than 24 hours. - 有效期
- 24 months
-
- 背景
- Angiogenesis
- 分子量
- 627.73 g/mol
- CAS-编号
- 211915-06-9
-